Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 50(2); 2018 > Article
Original Article Light Alcohol Drinking and Risk of Cancer: A Meta-Analysis of Cohort Studies
Yoon-Jung Choi, MD1, Seung-Kwon Myung, MD, PhD1,2,3,, Ji-Ho Lee, MD1,a
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(2):474-487.
DOI: https://doi.org/10.4143/crt.2017.094
Published online: May 22, 2017

1Department of Family Medicine and Center for Cancer Prevention and Detection, Hospital, National Cancer Center, Goyang, Korea

2Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea

3Cancer Epidemiology Branch, Division of Cancer Epidemiology and Prevention, Research Institute, National Cancer Center, Goyang, Korea

Correspondence: Seung-Kwon Myung, MD, PhD Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-0479 Fax: 82-31-920-2606 E-mail: msk@ncc.re.kr
aPresent address: Health Medical Center, Gangneung Asan Hospital, Gangneung, Korea
• Received: February 22, 2017   • Accepted: May 16, 2017

Copyright © 2018 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 25,067 Views
  • 831 Download
  • 109 Web of Science
  • 104 Crossref
  • 129 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    The purpose of this study was to determine whether light alcohol drinking increases the risk of cancer by using a meta-analysis of cohort studies because the newly revised 2015 European Code against Cancer fourth edition on alcohol and cancer was based on critical flaws in the interpretation and citation of the previous meta-analyses.
  • Materials and Methods
    PubMed and EMBASE were searched in April, 2016. Two authors independently reviewed and selected cohort studies on the association between very light (≤ 0.5 drink/day), light (≤ 1 drink/day), or moderate drinking (1-2 drinks/day) and the risk of cancer incidence and mortality. A pooled relative riskwith its 95% confidence intervalwas calculated by a random-effects meta-analysis. Main outcome measures were cancer incidence and mortality.
  • Results
    A total of 60 cohort studies from 135 articles were included in the final analysis. Very light drinking or light drinking was not associated with the incidence of most cancers except for female breast cancer in women and male colorectal cancer. Conversely, light drinking was associated with a decreased incidence of both female and male lung cancer significantly and both female and male thyroid cancer marginally significantly. Moderate drinking significantly increased the incidence of male colorectal cancer and female breast cancer,whereas it decreased the incidence of both female and male hematologic malignancy.
  • Conclusion
    We found that very light or light alcohol drinking was not associated with the risk of most of the common cancers except for the mild increase in the incidence of breast cancer in women and colorectal cancer in men.
  • Key words: Alcohols, Neoplasms, Cancer, Cohort studies, Meta-analysis
Alcohol is classified as Group 1 carcinogen by the International Agency for Research on Cancer (IARC), which category is used when there is sufficient evidence of carcinogenicity in humans [1]. However, it was usually excessive alcohol drinking that was condemned for causing cancer, and light or moderate alcohol consumption has been conceived as acceptable or even encouraged because of its known benefits in preventing cardiovascular diseases. Previously in 2003, the third edition of European Code against Cancer (ECAC) recommended that “If you drink alcohol, whether beer, wine or spirits, moderate your consumption to two drinks per day if you are a man or one drink per day if you are a woman." [2,3]. In 2015, the IARC published an article involving the newly revised ECAC fourth edition on alcohol drinking and cancer, which recommends “If you drink alcohol of any type, limit your drinking. Not drinking is better for cancer prevention." [4].
Since the publication of the ECAC fourth edition, however, Prof. Myung, the corresponding author of this paper claimed in the letter to the editor that the new ECAC on alcohol should be corrected because there were considerable critical flaws in the interpretation and citation of the existing observational epidemiological studies and meta-analyses on the association between light alcohol drinking (≤ 1 drink/day or 12.5 g/day) and the risk of cancer [5]. He criticized that the authors of the ECAC fourth edition did not consider the difference in findings between case-control studies and cohort studies: there was no significant association between light alcohol drinking and the risk of oropharyngeal cancer and colon cancer in the meta-analysis of cohort studies, whereas light alcohol drinking increased the risk of oropharyngeal cancer and colorectal cancer in the meta-analysis of case-control studies. Moreover, they incorrectly used the data for “moderate drinking (2-3 drinks/day)” or just “drinking” instead of “light drinking” in some analyses. Prof. Myung also published another letter to the editor [6] criticizing erroneous conclusions about the association between light alcohol drinking and the risk of cancer in Bagnardi et al.’s meta-analysis [7], which concluded that light alcohol drinking increased the risk of cancer of oropharynx, esophagus, and female breast and consequently contributed to the newly revised ECAC. Similarly, he pointed out that in Bagnardi et al.'s meta-analysis [7], except for female breast cancer, the meta-analysis of cohort studies did not show any significant association between light alcohol drinking and the risk of cancer of oropharynx, larynx, esophagus, colorectum, and liver, whereas the meta-analysis of case-control studies showed a significant positive association between light drinking and cancer of oropharynx and esophagus [6]. In summary, regarding the association between light alcohol drinking and the risk of cancer, the previous meta-analysis and the new ECAC fourth edition led to erroneous conclusions and incorrect recommendations due to the wrong interpretation and citations of the existing observational epidemiological studies.
Thus, we performed a comprehensive meta-analysis of cohort studies on this topic in order to investigate whether or not very light or light alcohol drinking as well as moderate alcohol drinking increased the risk of cancer.
1. Search strategy
We searched PubMed and EMBASE in March 31, 2016 using keywords “alcohol consumption,” “alcohol intake,” “cancer,” and “cohort study." We also reviewed the bibliographies of relevant articles to find additional studies.
2. Selection criteria
We included prospective or retrospective cohort studies reporting a multivariate adjusted relative risk (RR) with its 95% confidence interval (CI) for the association between light alcohol drinking (≤ 1 drink/day) and/or moderate alcohol drinking (1-2 drinks/day) and the risk of cancer. The current analysis involved general healthy populations. Thus, we excluded studies involving patients with underlying cancer and populations at high risk for a specific cancer such as patients with liver cirrhosis or hepatitis B virus carriers at high risk for liver cancer and those with Barrett’s esophagus at high risk for esophageal cancer. Also, we excluded (1) studies that adjusted for only age and/or sex in the multivariate analysis, (2) studies that used 0-2 drinks/day as criteria for light alcohol drinking instead of 1-2 drinks/day, and (3) studies that used 0.5 drink/day or more as a reference value.
3. Selection of relevant studies
Two authors (Y.-J. Choi and J.-H. Lee) of the current study independently selected relevant studies in the first screening process. Any disagreements were solved by discussion and in consult with a third author (S.-K. Myung). If data were duplicated or shared in more than one article, we included the more comprehensive or more recently published article for the analysis.
4. Main analysis and subgroup analysis
We investigated the risk of each type of cancer in both incidence and mortality according to different levels of alcohol drinking: very light drinking (≤ 0.5 drink/day), light drinking (≤ 1 drink/day), and moderate drinking (1-2 drinks /day). In general, one drink of alcohol corresponds to one unit of alcohol (12.5 g) which is contained in one glass of beer (355 mL), one glass of wine, and a single shot of hard liquor. However, since a number of studies used up to 15 g/day as 1 drink/day, we accepted up to 15 g as 1 drink of alcohol. The 7 drinks/wk, 105 g/wk, 30 drinks/mo, and 15 ounce/mo were considered equivalent to 1 drink/day or light drinking. Likewise, 3.5 drink/wk, 52.5 g/wk, 15 drinks/mo, and 7.5 ounce/mo were considered as 0.5 drink/day or very light drinking. Also, 15-30 g/day, 7-14 drinks/wk, 105-210 g/wk, 30-60 drinks/mo, and 15-30 ounce/mo were categorized to 1 to 2 drinks/day or moderate drinking. We chose the upper limit of the range of drinking to categorize levels of drinking: 5-15 g/day of drinking was considered as light drinking; if the upper limit exceeded 15 g/day, then it was categorized as moderate drinking. We performed the subgroup meta-analysis by type of cancer and gender.
5. Assessment of methodological quality of included studies
The methodological quality of the included studies was based on the Newcastle-Ottawa Scale (NOS) [8]. This scale has a star system (range, 0 to 9 stars) for the assessment. Standard criteria for high quality have not been established. Regarding outcome assessment, a star was given for a follow-up period of ≥ 5 years and a follow-up rate of ≥ 90%.
6. Statistical analysis
We used the adjusted RR with its 95% CI in order to compute a pooled RR with its 95% CI. Heterogeneity was assessed by Higgins I2, which is the percentage of total variation across the studies as follows:
I2=100%×(Q-df)/Q,
where df refers to degrees of freedom, and Q refers to Cochran's heterogeneity statistics [9]. An I2 value lies between 0% (no observed heterogeneity) and 100% (maximal heterogeneity). In general, an I2 greater than 50% is considered to have substantial heterogeneity. We used a randome-ffects model meta-analysis based on the DerSimonian and Laird method because most cohort studies were conducted in the different populations [10,11]. A STATA ver. 13.1 software (StataCorp LP, College Station, TX) was used for statistical analysis.
1. Selection of relevant studies
Fig. 1 shows a flow diagram of how we selected relevant studies. We identified a total of 4,721 articles consisting of 3,264 articles from PubMed and 1,457 articles from EMBASE. We excluded 787 duplicate articles and 3,503 articles that did not meet the selection criteria after reviewing 3,934 articles based on titles and abstracts. After reviewing the full text of the remaining 431 articles along with additional 65 articles newly located from relevant bibliographies, 361 articles were excluded because of studies sharing an identical population (n=27), insufficient data (n=94), studies with no available data for outcome measures (n=53), review or meta-analysis (n=18), case-studies or other study designs (n=23), and no relevant studies (n=146). From a total of 135 articles, 60 cohort studies were included in the final analysis (references of 135 articles are presented in Supplementary Material).
2. Characteristics of studies included in the final analysis
All the 60 cohort studies included in the final analysis involved a total of 9,428,076 participants (5,478,133 women and 3,949,943 men). As an outcome measure, all studies reported cancer incidence, and 14 studies reported cancer mortality. The number of studies according to cancer organ site were as follows (incidence, mortality): oral cavity and oropharynx (n=5, n=2), esophagus (squamous cell carcinoma) (n=2), esophagus (adenocarcinoma) and cardia (n=3), stomach (n=9, n=2), colorectum (n=16, n=5), liver (n=2, n=2), pancreas (n=5, n=4), lung cancer (n=10, n=5), female breast (n=27, n=7), endometrium (n=9), ovary (n=5), prostate (n=14, n=4), kidney (n=7, n=1), bladder (n=4), hematologic malignancies (n=8, n=2), and skin (malignant melanoma) (n=3) (Table 1).
Studies were conducted in North America (n=30, n=10), Europe (n=21), and Asia (n=9, n=4) (Table 1). General characteristics of the studies included in the final analysis by cancer incidence and mortality are presented in S1 and S2 Tables.
3. Methodological quality of studies
S3 and S4 Tables show the methodological quality of the studies included in the analysis. The range of scores was 5 to 9 for cancer incidence and 6-8 for cancer mortality. The mean score was 6.8 for cancer incidence studies (n=121) and 6.9 for cancer mortality studies (n=14).
4. Very light alcohol drinking and the risk of cancer

1) Incidence

Table 2 shows the associations between cancer incidence and very light, light, and moderate alcohol drinking. Overall very light drinking (≤ 0.5 drink/day) was not associated with the incidence of most cancers. However, very light drinking was significantly associated with a decreased incidence of both female and male lung cancer (RR, 0.89; 95% CI, 0.84 to 0.93; I2=6.9%; n=3), female lung cancer (RR, 0.82; 95% CI, 0.70 to 0.95; I2=12.9%; n=2), whereas it increased the incidence of female breast cancer (RR, 1.04; 95% CI, 1.01 to 1.07; I2=3.7%; n=20). There was no significant association between very light drinking and the incidence of head and neck cancer, esophageal cancer, stomach cancer, colorectal cancer, pancreatic cancer, endometrial cancer, ovary cancer, prostate cancer, kidney cancer, bladder cancer, thyroid cancer, and hematologic malignancy.

2) Mortality

Table 3 shows the associations between cancer mortality and very light, light, and moderate alcohol drinking. Very light drinking reduced the mortality of both female and male lung cancer (RR, 0.81; 95% CI, 0.69 to 0.94; I2=0.0%; n=2), female lung cancer (RR, 0.70; 95% CI, 0.56 to 0.89; n=1) and female breast cancer (RR, 0.79; 95% CI, 0.64 to 0.97; I2=0.0%; n=2). There was no significant association between very light drinking and the mortality of colorectal cancer, gallbladder cancer, prostate cancer, and hematologic malignancy.
5. Light alcohol drinking and the risk of cancer

1) Incidence

As shown in Table 2, similar to the findings of very light alcohol drinking, overall light drinking (≤ 1 drink/day) was not associated with the incidence of most cancers. However, light drinking was significantly associated with a decreased incidence of both female and male lung cancer (RR, 0.91; 95% CI, 0.90 to 0.94; I2=0.0%; n=10), male lung cancer (RR, 0.91; 95% CI, 0.90 to 0.95; I2=0.0%; n=3), and female lung cancer (RR, 0.90; 95% CI, 0.87 to 0.94; I2=0.0%; n=4), whereas it increased the incidence of female breast cancer (RR, 1.09; 95% CI, 1.06 to 1.12; I2=32.8%; n=25) (Fig. 2), both female and male colorectal cancer (RR, 1.04; 95% CI, 1.01 to 1.06; I2=0.0; n=14), male colorectal cancer (RR, 1.06; 95% CI, 1.01 to 1.11; I2=0.0%; n=6) (Fig. 3), and both female and male malignant melanoma (RR, 1.44; 95% CI, 1.18 to 1.76; I2=0.0%; n=3). In the subgroup meta-analysis by type of male colorectal cancer, light drinking was not associated with the incidence of either colon cancer (RR, 1.02; 95% CI, 0.87 to 1.21; I2=0.0%; n=5) or rectal cancer (RR, 1.07; 95% CI, 0.69 to 1.64; I2=0.0%; n=3). Also, light drinking was marginally associated with a decreased incidence of both female and male thyroid cancer (RR, 0.89; 95% CI, 0.79 to 1.00; I2=0.0%; n=6). There was no significant association between light drinking and the incidence of oropharyngeal cancer, head and neck cancer, esophageal cancer, stomach cancer, liver cancer, pancreatic cancer, endometrial cancer, ovary cancer, prostate cancer, kidney cancer, bladder cancer, and hematologic malignancy.

2) Mortality

As shown in Table 3, light drinking reduced the mortality of female stomach cancer (RR, 0.65; 95% CI, 0.44 to 0.98; n=1) and male lung cancer (RR, 0.79; 95% CI, 0.70 to 0.87; I2=0.0%; n=5). There was no significant association between light drinking and the mortality of oropharyngeal cancer, esophageal cancer, larynx cancer, colorectal cancer, liver cancer, female gallbladder cancer, pancreatic cancer, breast cancer, cervical cancer, prostate cancer, and hematologic malignancy.
6. Moderate alcohol drinking and the risk of cancer

1) Incidence

As shown in Table 2, moderate drinking (1-2 drinks/day) increased the incidence of both female and male oropharyngeal cancer (RR, 1.12; 95% CI, 1.01 to 1.24; I2=19.5%; n=3), female oropharyngeal cancer (RR, 1.18; 95% CI, 1.05 to 1.33; I2=0.0%; n=3), female larynx cancer (RR, 1.74; 95% CI, 1.25 to 2.41; n=1), both female and male squamous cell esophageal cancer (RR, 1.98; 95% CI, 1.25 to 3.14; I2=0.0%; n=2), both female and male colorectal cancer (RR, 1.10; 95% CI, 1.03 to 1.19; I2=41.0%; n=6), male colorectal cancer (RR, 1.19; 95% CI, 1.06 to 1.35; I2=10.6%; n=6), female breast cancer (RR, 1.13; 95% CI, 1.11 to 1.15; I2=0%; n=15), and both female and male malignant melanoma (RR, 1.77; 95% CI, 1.35 to 2.33; I2=0.0%; n=2). Also, it was marginally significantly associated with an increased incidence of female and male liver cancer (RR, 1.26; 95% CI, 1.00 to 1.58; I2=0.0%; n=2). On the contrary, moderate drinking reduced the incidence of both female and male kidney cancer (RR, 0.93; 95% CI, 0.86 to 1.00; I2=0.0%; n=3), female kidney cancer (RR, 0.93; 95% CI, 0.80 to 0.94; n=1), both female and male thyroid cancer (RR, 0.68; 95% CI, 0.56 to 0.84; I2=0.0%; n=3), female thyroid cancer (RR, 0.67; 95% CI, 0.53 to 0.85; I2=0.0%; n=2), and both female and male hematologic malignancy (RR, 0.89; 95% CI, 0.81 to 0.99; I2=52.3%; n=6). There was no significant association between moderate drinking and the incidence of head and neck cancer, adenomatous esophageal cancer and cardia, stomach cancer, pancreatic cancer, lung cancer, endometrial cancer, ovary cancer, prostate cancer, and bladder cancer.

2) Mortality

As shown in Table 3, overall moderate drinking was not associated with the mortality of most cancers. However, it increased the mortality of female colorectal cancer (RR, 2.51; 95% CI, 1.31 to 4.82; n=1) and female breast cancer (RR, 1.04; 95% CI, 1.01 to 1.07; I2=0.0%; n=2), while it reduced the mortality of male kidney cancer (RR, 0.46; 95% CI, 0.23 to 0.93; n=1).
1. Principal findings
In the current large scale meta-analysis of cohort studies, we found that compared with nondrinking or occasional alcohol drinking, very light (≤ 0.5 drink/day) or light (≤ 1 drink/day did not increase the incidence of most cancers except for female breast cancer and male colorectal cancer by up to 9% and 6%, respectively. Conversely, light drinking was associated with a decreased incidence of both female and male lung cancer significantly and both female and male thyroid cancer marginally significantly. In the meantime, moderate drinking, i.e., 1 to 2 drink/day significantly increased the incidence of two types of cancer, male colorectal cancer and female breast cancer, whereas it decreased the incidence of both female and male hematologic malignancy. Also, there is a limitation to draw definite conclusions on the associations between very light or light drinking and the risk of several types of cancer such as lung cancer, malignant melanoma, and rectal cancer in incidence along with those associations in mortality and the associations between moderate drinking and the risk of most cancers except for male colorectal cancer, female breast cancer, and hematologic malignancy in both incidence and mortality because of a paucity of the included studies.
2. Comparison with previous findings
Our conclusion on the association between light drinking and the risk of cancer are inconsistent with those from a previous large scale meta-analysis of observational epidemiological studies. Bagnardi et al.’s meta-analysis [7] of 222 articles which included case-control studies and cohort studies published before December 2010 concluded that light drinking (1 drink/day) increased the risk of cancer of oral cavity, pharynx, esophagus, and female breast [6]. As mentioned before in the introduction section, however, they did not consider the difference in findings between case-control studies and cohort studies and drew a wrong conclusion based on the findings from combining the results of both case-control studies and cohort studies. As Prof. Myung pointed out in his letter, except for breast cancer, the subgroup meta-analysis of cohort studies which generally provide a higher level of evidence than case-control studies did not show any significant association between light alcohol drinking and the risk of cancers of oral cavity, pharynx, and esophagus although light drinking was significantly associated with the increased risk of these cancers in the subgroup meta-analysis of case-control studies. Therefore, Bagnardi et al.’s meta-analysis [7] should have concluded that overall light drinking was not associated with the risk of cancer, although it increased the risk of female breast cancer slightly.
After the publication of Bagnardi et al.’s meta-analysis [7], the 2015 newly revised ECAC fourth edition changed its recommendation on drinking from “Moderate your consumption to two drinks per day if you are a man or one drink per day if you are a woman” to “Not drinking is better for cancer prevention” based on the similar conclusions to those from Bagnardi et al. [7]. The ECAC fourth edition also did not consider the difference in findings between case-control studies and cohort studies and moreover wrongly used data for moderate drinking or just drinking instead of light drinking for the meta-analysis.
3. Meaning and implications of the current findings for policy makers and clinicians
In our study, except for only two types of cancer, female breast cancer and male colorectal cancer, very light or light drinking was not associated with the risk of most cancers. Although the incidence of malignant melanoma was increased with light drinking, it remains inconclusive due to a small number of included studies. As for female breast cancer, its incidence was increased at even the level of very light drinking (≤ 0.5 drink/day), which can be interpreted that there is no safe level for alcohol drinking regarding female breast cancer. Also, light drinking (≤ 1 drink/day) was associated with the increased incidence of male colorectal cancer. However, except for these two types of cancer, there was no sufficient evidence to support that very light or light drinking up to 1 drink/day increases the risk of most of cancers. On the contrary, light drinking significantly decreased the incidence of both female and male lung cancer significantly and thyroid cancer marginally significantly. Thus, our findings imply that very light or light drinking has both benefits and harms in cancer prevention according to types of cancers.
4. Possible mechanisms for the main findings
The possible mechanisms on the association between alcohol consumption and the risk of breast cancer include the effect of alcohol on estrogen levels and estrogen receptor in mammary epithelial cells, the carcinogenic effect of ethanol metabolites, the effect of ethanol on epigenetic regulation of gene expression in the breast [42]. As for colon cancer, potential mechanisms to be examined in human-based studies are acetaldehyde production in the colon, cell proliferation due to ethanol or acetaldehyde exposure, and alterations in DNA repair mechanisms [43]. However, it still remains unclear why even very light or light drinking levels increase the incidence of female breast cancer and male colorectal cancer unlike the remaining common cancers.
In the meantime, very light or light drinking was associated with the decreased incidence of lung cancer significantly and thyroid cancer marginally significantly. It has been suggested that the protective effect of low or moderate alcohol consumption on lung cancer is attributable to its anti-inflammatory effects through lower plasma concentration of several systemic biomarkers of inflammation compared with no consumption [44], antioxidant effects in tumor promotion and progression [45], and anti-carcinogenic effects through induction of protective enzymes such as carcinogen detoxification enzymes [46,47]. However, it remains unclear why these effects would be specific for lung cancer. Also, the possible biological mechanisms on the inverse association between alcohol consumption and the risk of thyroid cancer are the protective effect on developing thyroid cancer by decreased levels of thyroid-stimulating hormone and the direct toxic effect on thyroid cells and consequently reduction of thyroid volume [48].
5. Strengths of the current meta-analysis
This is the first meta-analysis of cohort studies that comprehensively investigated the association between very light and light alcohol drinking and the risk of a variety of cancers. Our study has its originality in that for the first time, we claim that overall light alcohol drinking is not associated with the risk of most of the common cancers except for female breast cancer and male colorectal cancer. Our findings refute the newly revised ECAC fourth edition on alcohol drinking and cancer and those from Bagnardi et al.’s meta-analysis [7].
6. Limitations
There are several limitations in our study. First, except for breast cancer, colorectal cancer, and lung cancer, due to a paucity of data on very light or light drinking for most cancers, we were unable to clearly evaluate the associations between very light or light drinking and most cancers. Thus, further studies are necessary to confirm these associations. Second, there might be possible interactions between drinking and other factors such as smoking on the development of breast cancer and colorectal cancer. Although all the included cohort studies adjusted various factors in each multivariable analysis, those factors varied across the studies. For example, however, because most studies included the important factors affecting the development of breast cancer such as age, smoking, age at menopause, age at first birth, family history of breast cancer, hormone replacement therapy, and oral contraceptives, the effect of other unknown confounding factors would be minimal. Last, the generalization of our findings is limited because a small number of cohort studies among Asian populations were included in our analysis. More cohort studies are required to investigate that our findings can be applied to Asian populations.
Our meta-analysis of cohort studies found that compared with non or occasional alcohol drinking, very light or light drinking was not associated with the risk of most cancers except for female breast cancer and male colorectal cancer with a small increase in incidence. Although the IARC re-published The ECAC 4th Edition: Alcohol Drinking and Cancer in December 2016 [49] with a few corrections of data cited on the association between light alcohol drinking and cancer risk, they still did not consider the difference in findings between case-control studies and cohort studies and stick to the previously revised recommendation. Therefore, we suggest that the revision of the current ECAC fourth edition on alcohol drinking and cancer should be seriously considered from “If you drink alcohol of any type, limit your drinking. Not drinking is better for cancer prevention” to “If you drink alcohol of any type, limit your drinking. Not drinking is better in order to prevent breast cancer in women and colorectal cancer in men.”
Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).
crt-2017-094-suppl1.pdf
crt-2017-094-suppl2.pdf
crt-2017-094-suppl3.pdf
crt-2017-094-suppl4.pdf

Conflict of interest relevant to this article was not reported.

Fig. 1.
Flow diagram of identification of relevant studies.
crt-2017-094f1.gif
Fig. 2.
Association between light alcohol drinking (≤ 1 drink/day) and the risk of female breast cancer in a random-effects meta-analysis. RR, relative risk; CI, confidence interval.
crt-2017-094f2.gif
Fig. 3.
Association between light alcohol drinking (≤ 1 drink/day) and the risk of male colorectal cancer in a random-effects meta-analysis. RR, relative risk; CI, confidence interval.
crt-2017-094f3.gif
Table 1.
Number of articles and studies by organ site and country among 135 articles and 60 cohort studies
Category Incidence
 Mortality
No. of articles No. of studies No. of articles No. of studies
Site of cancer
 Upper digestive tract
  Oral and pharynx 5 5 2 2
  Esophagus (SCC) 2 2 5 4
  Esophagus (ADC) and cardia 3 3 NA NA
  Head and neck 2 2 NA NA
 Gastrointestinal tract
  Stomach (non-cardia) 11 9 2 2
  Colorectum 16 16 6 5
  Colon 10 10 NA NA
  Rectum 9 9
 Hepatobiliary system
  Liver 2 2 2 2
  Pancreas 5 5 4 4
  Gallbladder NA NA 1 1
 Respiratory tract
  Lung 10 10 6 5
  Larynx 1 1 1 1
 Women's cancer
  Breast (female) 34 27 7 7
  Endometrium 9 9 NA NA
  Ovary 5 5 NA NA
  Cervix/Uterus 2 2 1 1
 Men's cancer
  Prostate 15 14 4 4
 Urological system
  Kidney 7 7 1 1
  Bladder 4 4 NA NA
 Others
  Thyroid 6 6 NA NA
  Hematologic malignancy 8 8 2 2
  Malignant melanoma 3 3 NA NA
Country
 Asia
  China 3 2 NA NA
  Japan 5 4 2 2
  Korea 3 2 1 1
  Singapore 3 1 NA NA
  Honk Kong NA NA 1 1
 North America
  US 70 28 9 9
  Canada 4 2 1 1
 Europe
  UK 5 5 NA NA
  Sweden 6 3 NA NA
  Norway 1 1 NA NA
  Netherland 10 3 NA NA
  Lithuania 2 2 NA NA
  France 2 2 NA NA
  Finland 1 1 NA NA
  European countries 1 1 NA NA
  Denmark 5 3 NA NA

SCC, squamous cell carcinoma; ADC, adenocarcinoma; NA, not available.

Table 2.
Association between very light, light, and moderate alcohol drinking and cancer incidence
Site of cancer Total No. of studies Population Very light drinking (≤ 0.5 drink/day)
 Light drinking (≤ 1 drink/day)
 Moderate drinking (1-2 drinks/day)
No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%)
Head and neck 2 Women/Men 1 1.11 (0.75-1.65) NA 2 1.00 (0.75-1.33) 0.0 2 1.18 (0.67-2.07) 63.8
Oral and pharynx 5 Women/Men 0 NA NA 4 0.96 (0.84-1.11) 68.9 3 1.12 (1.01-1.24) 19.5
Women 0 NA NA 3 0.95 (0.75-1.19) 77.6 3 1.18 (1.05-1.33) 0.0
Men 0 NA NA 1 0.89 (0.79-1.00) NA 2 1.04 (0.93-1.17) 0.0
Larynx 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
Women 0 NA NA 1 1.13 (0.75-1.70) NA 1 1.74 (1.25-2.41) NA
Men 0 NA NA 0 NA NA 0 NA NA
Esophagus (SCC) 2 Women/Men 1 0.85 (0.42-1.73) NA 2 1.45 (0.90-2.33) 0.0 2 1.98 (1.25-3.14) 0.0
Women 0 NA NA 0 NA NA 0 NA NA
Men 0 NA NA 1 1.22 (0.62-2.44) NA 1 1.87 (0.99-3.53) NA
Esophagus (ADC) and cardia 3 Women/Men 1 1.17 (0.69-1.98) NA 3 0.83 (0.52-1.33) 44.5 3 0.81 (0.56-1.17) 0.0
Women 0 NA NA 0 NA NA 0 NA NA
Men 0 NA NA 0 NA NA 0 NA NA
Stomach, non-cardia 11 Women/Men 3 1.00 (0.78-1.30) 0.0 7 1.00 (0.95-1.07) 0.0 6 0.91 (0.78-1.06) 0.0
Women 1 1.11 (0.71-1.73) NA 0 NA NA 0 NA NA
Men 2 1.04 (0.66-1.64) 0.0 2 1.01 (0.92-1.11) 0.0 2 0.91 (0.68-1.20) 0.0
Colorectum 16 Women/Men 6 1.10 (0.94-1.28) 39.7 14 1.04 (1.01-1.06) 0.0 10 1.10 (1.03-1.19) 41.0
Women 2 0.92 (0.78-1.08) 0.0 7 1.02 (0.98-1.06) 0.0 5 1.04 (0.95-1.13) 4.4
Men 3 1.31 (0.92-1.86) 47.3 6 1.06 (1.01-1.11) 0.0 6 1.19 (1.06-1.35) 10.6
Colon 10 Women/Men 2 0.91 (0.55-1.49) 79.4 11 0.99 (0.93-1.05) 1.4 6 1.01 (0.88-1.15) 43.3
Women 0 NA NA 5 1.12 (0.90-1.40) 60.4 5 1.03 (0.91-1.17) 28.4
Men 1 1.42 (0.83-2.45) NA 5 1.02 (0.87-1.21) 0.0 5 1.08 (0.89-1.31) 0.0
Rectum 9 Women/Men 2 1.47 (0.95-2.29) 0.0 10 1.04 (0.96-1.12) 0.5 7 1.03 (0.94-1.12) 0.0
Women 0 NA NA 4 1.02 (0.93-1.11) 0.0 3 0.99 (0.90-1.09) 0.0
Men 0 NA NA 3 1.07 (0.69-1.64) 0.0 2 1.35 (0.77-2.35) 0.0
Liver 2 Women/Men 0 NA NA 2 0.95 (0.76-1.20) 0.0 2 1.26 (1.00-1.58) 0.0
Women 0 NA NA 1 0.94 (0.72-1.21) NA 1 1.20 (0.93-1.55) NA
Men 0 NA NA 0 NA NA 0 NA NA
Pancreas 5 Women/Men 4 1.06 (0.87-1.30) 0.0 3 1.02 (0.83-1.26) 6.3 3 1.03 (0.86-1.23) 0.0
Women 0 NA NA 0 NA NA 1 1.01 (0.53-1.91) NA
Men 2 1.25 (0.90-1.74) 0.0 1 1.39 (0.75-2.56) NA 1 1.24 (0.66-2.32) NA
Lung 10 Women/Men 3 0.89 (0.84-0.93) 6.9 10 0.91 (0.90-0.94) 0.0 8 0.98 (0.91-1.07) 50.0
Women 2 0.82 (0.70-0.95) 12.9 4 0.90 (0.87-0.94) 0.0 4 1.05 (0.99-1.11) 0.0
Men 1 0.86 (0.71-1.03) NA 3 0.91 (0.90-0.95) 0.0 4 0.98 (0.82-1.16) 52.1
Breast (female) 34 Women 20 1.04 (1.01-1.07) 3.7 25 1.09 (1.06-1.12) 32.8 15 1.13 (1.11-1.15) 0.0
Endometrium 9 Women 6 0.95 (0.80-1.12) 52.1 7 0.98 (0.93-1.03) 0.0 4 0.93 (0.84-1.04) 6.8
Ovary 5 Women 2 1.00 (0.82-1.22) 0.0 5 1.02 (0.88-1.20) 52.4 4 1.20 (0.92-1.56) 66.6
Cervix and uterus 2 Women NA NA NA 2 1.02 (0.88-1.19) 0.0 2 0.99 (0.83-1.17) 0.0
Prostate 15 Men 3 1.16 (0.94-1.44) 0.0 13 1.04 (0.97-1.11) 50.0 3 1.04 (0.96-1.11) 0.0
Kidney 7 Women/Men 2 0.73 (0.50-1.08) 0.0 7 0.90 (0.81-1.00) 0.0 3 0.93 (0.86-1.00) 0.0
Women 1 0.75 (0.45-1.29) NA 2 0.79 (0.41-1.50) 66.9 1 0.93 (0.80-0.94) NA
Men NA NA NA 3 0.90 (0.78-1.03) 0.0 1 0.94 (0.64-1.03) NA
Bladder 4 Women/Men 2 1.22 (0.82-1.82) 27.5 5 1.09 (0.97-1.23) 0.0 4 1.06 (0.77-1.47) 64.2
Women 0 NA NA 1 1.05 (0.92-1.21) NA 1 0.91 (0.77-1.07) NA
Men 0 NA NA 1 1.31 (0.80-2.13) NA 0 NA NA
Thyroid 6 Women/Men 1 1.01 (0.76-1.36) NA 6 0.89 (0.79-1.00) 0.0 3 0.68 (0.56-0.84) 0.0
Women 0 NA NA 5 0.89 (0.78-1.01) 0.0 2 0.67 (0.53-0.85) 0.0
Men 0 NA NA 1 0.62 (0.25-1.54) NA 1 0.69 (0.40-1.20) NA
Hematologic malignancy 8 Women/Men 3 1.05 (0.87-1.26) 15.1 6 0.98 (0.91-1.05) 41.4 6 0.89 (0.81-0.99) 52.3
Women 1 1.16 (0.88-1.54) NA 4 0.99 (0.93-1.06) 0.0 3 0.91 (0.81-1.02) 0.0
Men 0 NA NA 2 0.98 (0.81-1.19) 54.2 2 0.90 (0.78-1.04) 0.0
Malignant melanoma 3 Women/Men 0 NA NA 3 1.44 (1.18-1.76) 0.0 2 1.77 (1.35-2.33) 0.0
Women 0 NA NA 2 1.32 (0.97-1.79) 0.0 1 1.70 (0.90-3.10) NA
Men 0 NA NA 0 NA NA 1 0.90 (0.20-3.00) NA

RR, relative risk; CI, confidence interval; NA, not applicable; SCC, squamous cell carcinoma; ADC, adenocarcinoma.

Table 3.
Association between very light, light, and moderate alcohol drinking and cancer mortality
Site of cancer Total No. of studies Population Very light drinking (≤ 0.5 drink/day)
 Light drinking (≤ 1 drink/day)
 Moderate drinking (1-2 drinks/day)
No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%)
Oral and pharynx 2 Women/Men 0 NA NA 0 NA NA 0 NA NA
Women 0 NA NA 0 NA NA 0 NA NA
Men 0 NA NA 2 0.71 (0.24-2.16) 72.0 1 0.75 (0.27-2.06) NA
Esophagus 4 Women/Men 0 NA NA 0 NA NA 0 NA NA
Women 0 NA NA 0 NA NA 0 NA NA
Men 0 NA NA 4 1.17 (0.98-1.39) 0.0 2 1.46 (0.93-2.16) 0.0
Larynx 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
Women 0 NA NA 0 NA NA 0 NA NA
Men 0 NA NA 1 1.31 (0.60-2.85) NA 1 0.87 (0.32-2.35) NA
Stomach 2 Women/Men 0 NA NA 3 0.81 (0.58-1.12) 49.5 2 1.11 (0.79-1.56) 43.6
Women 0 NA NA 1 0.65 (0.44-0.98) NA 1 1.48 (0.85-2.57) NA
Men 0 NA NA 2 0.95 (0.83-1.10) 0.0 1 1.00 (0.85-1.18) NA
Colorectum 6 Women/Men 2 0.88 (0.70-1.12) 0.0 6 0.97 (0.83-1.14) 32.6 2 1.55 (0.67-3.58) 82.4
Women 1 0.74 (0.53-1.03) NA 4 0.79 (0.58-1.06) 26.3 1 2.51 (1.31-4.82) NA
Men 2 1.06 (0.72-1.55) 0.0 5 1.11 (0.95-1.28) 0.0 1 1.06 (0.80-1.40) NA
Liver 2 Women/Men 0 NA NA 2 0.92 (0.81-1.04) 0.0 2 1.00 (0.88-1.14) 37.7
Women 0 NA NA 2 0.78 (0.48-1.25) 0.0 1 1.80 (0.90-1.10) NA
Men 0 NA NA 2 0.93 (0.81-1.06) 0.0 2 0.98 (0.91-1.07) 0.0
Gallbladder 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
Women 1 1.49 (0.59-3.74) NA 1 1.14 (0.28-4.70) NA 0 NA NA
Men 0 NA NA 0 NA NA 0 NA NA
Pancreas 4 Women/Men 0 NA NA 4 0.93 (0.78-1.11) 22.0 1 0.95 (0.72-1.27) 0.0
Women 0 NA NA 1 0.66 (0.35-1.23) NA 1 0.50 (0.12-2.05) NA
Men 1 0.52 (0.23-1.15) NA 3 1.01 (0.55-1.85) 55.8 1 0.98 (0.73-1.31) NA
Lung 5 Women/Men 2 0.81 (0.69-0.94) 0.0 6 0.90 (0.79-1.04) 49.3 0 NA NA
Women 1 0.70 (0.56-0.89) NA 3 1.03 (0.80-1.31) 43.1 1 0.94 (0.45-1.94) NA
Men 2 0.84 (0.68-1.03) 0.0 5 0.79 (0.70-0.87) 0.0 1 0.78 (0.68-0.90) NA
Breast 7 Women 2 0.79 (0.64-0.97) 0.0 6 1.06 (0.97-1.16) 31.5 2 1.04 (1.01-1.07) 0.0
Cervix/Uterus 1 Women 0 NA NA 1 1.09 (0.50-2.35) NA 1 1.10 (0.25-4.79) NA
Prostate 4 Men 2 0.92 (0.68-1.25) 0.0 1 1.14 (0.85-1.52) 0.0 1 1.75 (0.72-4.22) NA
Kidney 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
Women 0 NA NA 0 NA NA 0 NA NA
Men 0 NA NA 1 0.63 (0.35-1.12) NA 1 0.46 (0.23-0.93) NA
Hematologic malignancy 2 Women/Men 0 NA NA 2 1.24 (0.40-3.86) 55.6 1 1.00 (0.63-1.60) NA
Women 0 NA NA 1 3.26 (0.79-13.48) NA 0 NA NA
Men 1 0.87 (0.49-1.53) NA 3 0.80 (0.54-1.18) 1.9 1 1.00 (0.63-1.60) NA

RR, relative risk; CI, confidence interval; NA, not applicable.

  • 1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt E):1–538.
  • 2. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, et al. European Code Against Cancer and scientific justification: third version (2003). Ann Oncol. 2003;14:973–1005. ArticlePubMedPDF
  • 3. Schuz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiol. 2015;39 Suppl 1:S1–10. ArticlePubMed
  • 4. Scoccianti C, Cecchini M, Anderson AS, Berrino F, Boutron-Ruault MC, Espina C, et al. European code against cancer 4th edition: alcohol drinking and cancer. Cancer Epidemiol. 2015;39 Suppl 1:S67–74. ArticlePubMed
  • 5. Myung SK. Insufficient evidence on the association between light alcohol drinking and the risk of cancer: on the need for correction of the newly revised European Code against Cancer 4th edition. Cancer Epidemiol. 2016;44:174–5. ArticlePubMed
  • 6. Myung SK. Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis. Ann Oncol. 2016;27:2138.ArticlePMCPDF
  • 7. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol. 2013;24:301–8. ArticlePubMedPDF
  • 8. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa: Ottawa Hospital Research Institute; 2017. [cited 2017 May 2]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  • 9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. ArticlePubMed
  • 10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. ArticlePubMed
  • 11. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111. ArticlePubMed
  • 12. Simon MS, Carman W, Wolfe R, Schottenfeld D. Alcohol consumption and the risk of breast cancer: a report from the Tecumseh Community Health Study. J Clin Epidemiol. 1991;44:755–61. ArticlePubMed
  • 13. Gapstur SM, Potter JD, Sellers TA, Folsom AR. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol. 1992;136:1221–31. ArticlePubMedPDF
  • 14. van den Brandt PA, Goldbohm RA, van 't Veer P. Alcohol and breast cancer: results from The Netherlands Cohort Study. Am J Epidemiol. 1995;141:907–15. ArticlePubMedPDF
  • 15. Zhang Y, Kreger BE, Dorgan JF, Splansky GL, Cupples LA, Ellison RC. Alcohol consumption and risk of breast cancer: the Framingham Study revisited. Am J Epidemiol. 1999;149:93–101. ArticlePubMedPDF
  • 16. Feigelson HS, Calle EE, Robertson AS, Wingo PA, Thun MJ. Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes Control. 2001;12:895–902. ArticlePubMed
  • 17. Dumeaux V, Lund E, Hjartaker A. Use of oral contraceptives, alcohol, and risk for invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1302–7. ArticlePubMedPDF
  • 18. Horn-Ross PL, Canchola AJ, West DW, Stewart SL, Bernstein L, Deapen D, et al. Patterns of alcohol consumption and breast cancer risk in the California Teachers Study cohort. Cancer Epidemiol Biomarkers Prev. 2004;13:405–11. ArticlePubMedPDF
  • 19. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: A prospective cohort study. J Nat Cancer Inst. 2005;97:1601–8. ArticlePubMedPDF
  • 20. Mellemkjaer L, Bigaard J, Tjonneland A, Christensen J, Thomsen B, Johansen C, et al. Body composition and breast cancer in postmenopausal women: a Danish prospective cohort study. Obesity. 2006;14:1854–62. ArticlePubMed
  • 21. Tjonneland A, Christensen J, Olsen A, Stripp C, Thomsen BL, Overvad K, et al. Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 2007;18:361–73. ArticlePubMed
  • 22. Zhang SM, Lee IM, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol. 2007;165:667–76. ArticlePubMedPDF
  • 23. Kabat GC, Miller AB, Jain M, Rohan TE. Dietary intake of selected B vitamins in relation to risk of major cancers in women. Br J Cancer. 2008;99:816–21. ArticlePubMedPMCPDF
  • 24. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst. 2009;101:296–305. ArticlePubMedPDF
  • 25. Lew JQ, Freedman ND, Leitzmann MF, Brinton LA, Hoover RN, Hollenbeck AR, et al. Alcohol and risk of breast cancer by histologic type and hormone receptor status in postmenopausal women: the NIH-AARP Diet and Health Study. Am J Epidemiol. 2009;170:308–17. ArticlePubMedPMCPDF
  • 26. Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, et al. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. J Natl Cancer Inst. 2010;102:1422–31. ArticlePubMedPMCPDF
  • 27. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011;306:1884–90. ArticlePubMedPMC
  • 28. Kawai M, Minami Y, Kakizaki M, Kakugawa Y, Nishino Y, Fukao A, et al. Alcohol consumption and breast cancer risk in Japanese women: the Miyagi Cohort study. Breast Cancer Res Treat. 2011;128:817–25. ArticlePubMed
  • 29. Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 2013;105:1571–8. ArticlePubMedPMCPDF
  • 30. Falk RT, Maas P, Schairer C, Chatterjee N, Mabie JE, Cunningham C, et al. Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics. Am J Epidemiol. 2014;180:705–17. ArticlePubMedPMCPDF
  • 31. Park SY, Kolonel LN, Lim U, White KK, Henderson BE, Wilkens LR. Alcohol consumption and breast cancer risk among women from five ethnic groups with light to moderate intakes: the Multiethnic Cohort Study. Int J Cancer. 2014;134:1504–10. ArticlePubMedPMC
  • 32. Chhim AS, Fassier P, Latino-Martel P, Druesne-Pecollo N, Zelek L, Duverger L, et al. Prospective association between alcohol intake and hormone-dependent cancer risk: modulation by dietary fiber intake. Am J Clin Nutr. 2015;102:182–9. ArticlePubMedPDF
  • 33. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open. 2015;5:e007825ArticlePubMedPMC
  • 34. Klatsky AL, Li Y, Nicole Tran H, Baer D, Udaltsova N, Armstrong MA, et al. Alcohol intake, beverage choice, and cancer: a cohort study in a large kaiser permanente population. Perm J. 2015;19:28–34. ArticlePubMedPMCPDF
  • 35. Shin A, Sandin S, Lof M, Margolis KL, Kim K, Couto E, et al. Alcohol consumption, body mass index and breast cancer risk by hormone receptor status: Women' Lifestyle and Health Study. BMC Cancer. 2015;15:881.ArticlePubMedPMCPDF
  • 36. Nitta J, Nojima M, Ohnishi H, Mori M, Wakai K, Suzuki S, et al. Weight gain and alcohol drinking associations with breast cancer risk in Japanese postmenopausal women: results from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev. 2016;17:1437–43. ArticlePubMedPDF
  • 37. Chen K, Jiang Q, Ma X, Li Q, Yao K, Yu W, et al. Alcohol drinking and colorectal cancer: a population-based prospective cohort study in China. Eur J Epidemiol. 2005;20:149–54. ArticlePubMed
  • 38. Thygesen LC, Wu K, Gronbaek M, Fuchs CS, Willett WC, Giovannucci E. Alcohol intake and colorectal cancer: a comparison of approaches for including repeated measures of alcohol consumption. Epidemiology. 2008;19:258–64. ArticlePubMed
  • 39. Park JY, Mitrou PN, Dahm CC, Luben RN, Wareham NJ, Khaw KT, et al. Baseline alcohol consumption, type of alcoholic beverage and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition-Norfolk study. Cancer Epidemiol. 2009;33:347–54. ArticlePubMed
  • 40. Everatt R, Tamosiunas A, Virviciute D, Kuzmickiene I, Reklaitiene R. Consumption of alcohol and risk of cancer among men: a 30 year cohort study in Lithuania. Eur J Epidemiol. 2013;28:383–92. ArticlePubMed
  • 41. Cho S, Shin A, Park SK, Shin HR, Chang SH, Yoo KY. Alcohol drinking, cigarette smoking and risk of colorectal cancer in the Korean multi-center cancer cohort. J Cancer Prev. 2015;20:147–52. ArticlePubMedPMCPDF
  • 42. Liu Y, Nguyen N, Colditz GA. Links between alcohol consumption and breast cancer: a look at the evidence. Womens Health (Lond). 2015;11:65–77. ArticlePubMedPMC
  • 43. Oyesanmi O, Snyder D, Sullivan N, Reston J, Treadwell J, Schoelles KM. Alcohol consumption and cancer risk: understanding possible causal mechanisms for breast and colorectal cancers. Evid Rep Technol Assess (Full Rep). 2010;(197):1–151.
  • 44. Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P, et al. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J. 2004;25:2092–100. ArticlePubMedPDF
  • 45. Bianchini F, Vainio H. Wine and resveratrol: mechanisms of cancer prevention? Eur J Cancer Prev. 2003;12:417–25. ArticlePubMed
  • 46. Rohrmann S, Linseisen J, Boshuizen HC, Whittaker J, Agudo A, Vineis P, et al. Ethanol intake and risk of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol. 2006;164:1103–14. ArticlePubMedPDF
  • 47. Woodson K, Tangrea JA, Barrett MJ, Virtamo J, Taylor PR, Albanes D. Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers. J Natl Cancer Inst. 1999;91:1738–43. ArticlePubMedPDF
  • 48. Hong SH, Myung SK, Kim HS; Korean Meta-Analysis (KORMA) Study Group. Alcohol intake and risk of thyroid cancer: a meta-analysis of observational studies. Cancer Res Treat. 2017;49:534–47. ArticlePubMedPDF
  • 49. Scoccianti C, Cecchini M, Anderson AS, Berrino F, Boutron-Ruault MC, Espina C, et al. European Code against Cancer 4th Edition: alcohol drinking and cancer. Cancer Epidemiol. 2016;45:181–8. ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women
      Xinyi Li, Jinhee Hur, Yin Zhang, Mingyang Song, Stephanie A Smith-Warner, Liming Liang, Kenneth J Mukamal, Eric B Rimm, Edward L Giovannucci
      JNCI: Journal of the National Cancer Institute.2025; 117(5): 971.     CrossRef
    • ‘It’s T-shirt feminism’: exploring women’s perceptions of the appropriation of feminist messaging in alcohol brand marketing
      A. M. Atkinson, B. R. Meadows, H. Sumnall
      Drugs: Education, Prevention and Policy.2025; : 1.     CrossRef
    • Alcohol consumption and breast lesions: targets for risk-based screening in high-risk Italian women
      Sonia Cerrai, Alessio Lachi, Michela Franchini, Stefania Pieroni, Giada Anastasi, Marco Scalese, Anna Odone, Silvano Gallus, Luc Smits, Sabrina Molinaro
      Breast Cancer.2025;[Epub]     CrossRef
    • Lung Cancer and Lifestyle Factors
      Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
      Hematology/Oncology Clinics of North America.2024; 38(1): 171.     CrossRef
    • Breast Cancer and Lifestyle Factors
      Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
      Hematology/Oncology Clinics of North America.2024; 38(1): 137.     CrossRef
    • Association between lifestyle and dietary preference factors and conventional adenomas and serrated polyps
      Jue Xu, Peihan Chi, Kang Qin, Biao Li, Zhongxue Cheng, Zhecong Yu, Caixia Jiang, Yunxian Yu
      Frontiers in Nutrition.2024;[Epub]     CrossRef
    • Predicting lung cancer survival prognosis based on the conditional survival bayesian network
      Lu Zhong, Fan Yang, Shanshan Sun, Lijie Wang, Hong Yu, Xiushan Nie, Ailing Liu, Ning Xu, Lanfang Zhang, Mingjuan Zhang, Yue Qi, Huaijun Ji, Guiyuan Liu, Huan Zhao, Yinan Jiang, Jingyi Li, Chengcun Song, Xin Yu, Liu Yang, Jinchao Yu, Hu Feng, Xiaolei Guo,
      BMC Medical Research Methodology.2024;[Epub]     CrossRef
    • Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan and Korea
      Salma Nabila, Ji-Yeob Choi, Sarah Krull Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Aesun Shin, Melissa A. Merritt, Ryoko Katagiri, Xiao-Ou Shu, Norie Sawada, Akiko Tamakoshi, Ritsu Sakata, Atsushi Hozawa, Jeongseon Kim, Chisato Nagata, Sue K.
      Breast Cancer Research.2024;[Epub]     CrossRef
    • Design, synthesis, in silico, and pharmacological evaluation of novel quinoline derivatives containing substituted piperazine moieties as potential anti-breast cancer agents
      Muthiah Gnana Ruba Priya, Viswas Raja Solomon, Nagarajan Hemavathy, Jeyaraman Jeyakanthan, Dileep Kumar, Jahnavi Mahesh
      Results in Chemistry.2024; 7: 101359.     CrossRef
    • Sijunzi decoction enhances sensitivity of colon cancer cells to NK cell destruction by modulating P53 expression
      Xinxin Wang, Shufang Pan, Liangyan Chen, Chengchen Liang, Yueyi Zhu, Ke Zhou, Xiaolan Shi
      Journal of Ethnopharmacology.2024; 329: 118115.     CrossRef
    • The Lancet Breast Cancer Commission
      Charlotte E Coles, Helena Earl, Benjamin O Anderson, Carlos H Barrios, Maya Bienz, Judith M Bliss, David A Cameron, Fatima Cardoso, Wanda Cui, Prudence A Francis, Reshma Jagsi, Felicia Marie Knaul, Stuart A McIntosh, Kelly-Anne Phillips, Lukas Radbruch, M
      The Lancet.2024; 403(10439): 1895.     CrossRef
    • The Combined Effects of Alcohol Consumption and Smoking on Cancer Risk by Exposure Level: A Systematic Review and Meta-Analysis
      Seunghee Jun, Hyunjin Park, Ui-Jeong Kim, Hye Ah Lee, Bomi Park, Soon Young Lee, Sun Ha Jee, Hyesook Park
      Journal of Korean Medical Science.2024;[Epub]     CrossRef
    • Non-genetic factors and breast cancer: an umbrella review of meta-analyses
      Anneza Yiallourou, Katerina Pantavou, Georgios Markozannes, Antonis Pilavas, Andrea Georgiou, Andria Hadjikou, Mary Economou, Neophytos Christodoulou, Konstantinos Letsos, Elina Khattab, Chrystalleni Kossyva, Maria Constantinou, Melanie Theodoridou, Danie
      BMC Cancer.2024;[Epub]     CrossRef
    • Sex difference in alcohol consumption associated with colorectal cancer risk in Quzhou, China: A nested case-control study
      Shi-Ming Lai, Hong-Hong Zhu, Zhi-Juan Gan, Bi-Yun Zheng, Zhao-Hui Xu, Zhi-Cheng Wang, Xiao-Fang Liao
      Preventive Medicine Reports.2024; 44: 102807.     CrossRef
    • Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy
      Yanan Sun, Jiahe Hu, Rongfang Wang, Xinlian Du, Xiaoling Zhang, Jiaoting E, Shaoyue Zheng, Yuxin Zhou, Ruishu Mou, Xuedong Li, Hanbo Zhang, Ying Xu, Yuan Liao, Wenjie Jiang, Lijia Liu, Ruitao Wang, Jiuxin Zhu, Rui Xie
      Cancer Medicine.2024;[Epub]     CrossRef
    • Oncologists’ communication about tobacco and alcohol use during treatment for esophagogastric cancer: a qualitative observational study of simulated consultations
      Danique W. Bos-van den Hoek, Loïs F. van de Water, Pieter G. Vos, Meeke Hoedjes, Ruud Roodbeen, Bastiaan R. Klarenbeek, Debby Geijsen, Ellen M. A. Smets, Hanneke W. M. van Laarhoven, Inge Henselmans
      Supportive Care in Cancer.2024;[Epub]     CrossRef
    • The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis
      Shu-Yi Dong, Shuxin Ding, Zhen Meng, Bo Zou
      Future Science OA.2024;[Epub]     CrossRef
    • Alcoholic beverage consumption and female breast cancer risk: A systematic review and meta‐analysis of prospective cohort studies
      Ivneet Sohi, Jürgen Rehm, Marian Saab, Lavanya Virmani, Ari Franklin, Gonzalo Sánchez, Mihojana Jhumi, Ahmed Irshad, Hiya Shah, Daniela Correia, Pietro Ferrari, Carina Ferreira‐Borges, Beatrice Lauby‐Secretan, Gauden Galea, Susan Gapstur, Maria Neufeld, H
      Alcohol, Clinical and Experimental Research.2024; 48(12): 2222.     CrossRef
    • The global, regional, and national alcohol-related colorectal cancer burden and forecasted trends: results from the global burden of disease study 2021
      Jinfeng Yao, Guo Chen
      Frontiers in Nutrition.2024;[Epub]     CrossRef
    • Association of alcohol types, coffee and tea intake with mortality: prospective cohort study of UK Biobank participants
      Sylva M. Schaefer, Anna Kaiser, Inken Behrendt, Gerrit Eichner, Mathias Fasshauer
      British Journal of Nutrition.2023; 129(1): 115.     CrossRef
    • Magazines as contradictory spaces for alcohol messaging: a mixed method content and thematic analysis of UK women’s magazine representations of alcohol and its consumption
      A. M. Atkinson, B. R. Meadows, K. M. Ross-Houle, C. Smith, H. R. Sumnall
      Drugs: Education, Prevention and Policy.2023; 30(5): 474.     CrossRef
    • Sweetened beverages are associated with a higher risk of differentiated thyroid cancer in the EPIC cohort: a dietary pattern approach
      Raul Zamora-Ros, Valerie Cayssials, Ramon Clèries, Maria Torrents, Graham Byrnes, Elisabete Weiderpass, Maria Sandström, Martin Almquist, Marie-Christine Boutron-Ruault, Anne Tjønneland, Cecilie Kyrø, Verena A. Katzke, Charlotte Le Cornet, Giovanna Masala
      European Journal of Nutrition.2023; 62(1): 105.     CrossRef
    • Designing Effective Alcohol Warnings: Consumer Reactions to Icons and Health Topics
      Anna H. Grummon, Phoebe R. Ruggles, Thomas K. Greenfield, Marissa G. Hall
      American Journal of Preventive Medicine.2023; 64(2): 157.     CrossRef
    • Reinstating apoptosis using putative Bcl-xL natural product inhibitors: Molecular docking and ADMETox profiling investigations
      Ibrahim Damilare Boyenle, Abdeen Tunde Ogunlana, Abdul-Quddus Kehinde Oyedele, Babatunde Kazeem Olokodana, Nurudeen Owolabi, Abdulmalik Salahudeen, Oluwafemi Timothy Aderenle, Taiwo Oluwafisayomi Oloyede, Temitope Isaac Adelusi
      Journal of Taibah University Medical Sciences.2023; 18(3): 461.     CrossRef
    • Cancer Risk According to Alcohol Consumption Trajectories: A Population-based Cohort Study of 2.8 Million Korean Men
      Thi Tra Bui, Minji Han, Ngoc Minh Luu, Thi Phuong Thao Tran, Min Kyung Lim, Jin-Kyoung Oh
      Journal of Epidemiology.2023; 33(12): 624.     CrossRef
    • A Brief Intervention for Improving Alcohol Literacy and Addressing Harmful Alcohol Use Among Women Attending an Australian Breast Screening Service (Health4her): Protocol for a Hybrid Effectiveness-Implementation Trial
      Jasmin Grigg, Victoria Manning, Darren Lockie, Michelle Giles, Robin Bell, Peta Stragalinos, Chloe Bernard, Isabelle Volpe, Christopher J Greenwood, Liam Smith, Peter Bragge, Dan I Lubman
      JMIR Research Protocols.2023; 12: e44867.     CrossRef
    • Moderate wine consumption and cancer risk in context
      Ursula Fradera, Claudia Hammer, P. Roca
      BIO Web of Conferences.2023; 56: 04002.     CrossRef
    • Systemic treatment for metastatic colorectal cancer
      Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana
      World Journal of Gastroenterology.2023; 29(10): 1425.     CrossRef
    • Systemic treatment for metastatic colorectal cancer
      Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana
      World Journal of Gastroenterology.2023; 29(10): 1569.     CrossRef
    • Why Does Obesity as an Inflammatory Condition Predispose to Colorectal Cancer?
      Anna Maria Rychter, Liliana Łykowska-Szuber, Agnieszka Zawada, Aleksandra Szymczak-Tomczak, Alicja Ewa Ratajczak, Kinga Skoracka, Michalina Kolan, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
      Journal of Clinical Medicine.2023; 12(7): 2451.     CrossRef
    • Risky alcohol consumption among women in Australia attending breast screening services: an exploratory cross‐sectional study
      Jasmin Grigg, Victoria Manning, Ali Cheetham, Christopher J. Greenwood, George Youssef, Darren Lockie, Robin Bell, Peta Stragalinos, Chloe Bernard, Dan I. Lubman
      Addiction.2023; 118(8): 1493.     CrossRef
    • Alcohol consumption and all-cause and cause-specific mortality among US adults: prospective cohort study
      Yalan Tian, Jiahui Liu, Yue Zhao, Nana Jiang, Xiao Liu, Gang Zhao, Xia Wang
      BMC Medicine.2023;[Epub]     CrossRef
    • A brief intervention for improving alcohol literacy and reducing harmful alcohol use by women attending a breast screening service: a randomised controlled trial
      Jasmin Grigg, Victoria Manning, Darren Lockie, Michelle Giles, Robin J Bell, Peta Stragalinos, Chloe Bernard, Christopher J Greenwood, Isabelle Volpe, Liam Smith, Peter Bragge, Dan I Lubman
      Medical Journal of Australia.2023; 218(11): 511.     CrossRef
    • Associations between Liver Enzymes, Lifestyle Risk Factors and Pre-Existing Medical Conditions in a Population-Based Cross-Sectional Sample
      Onni Niemelä, Aini Bloigu, Risto Bloigu, Mauri Aalto, Tiina Laatikainen
      Journal of Clinical Medicine.2023; 12(13): 4276.     CrossRef
    • Gut Microbiota and Colorectal Cancer Risk Factors
      Hadi Feizi, Mohammad Ahangarzadeh Rezaee, Reza Ghotaslou, Mohammad Sadrkabir, Farhad Jadidi-Niaragh, Pourya Gholizadeh, Sepehr Taghizadeh, Khudaverdi Ghanbarov, Mehdi Yousefi, Hossein Samadi Kafil
      Current Pharmaceutical Biotechnology.2023; 24(8): 1018.     CrossRef
    • Effect of alcohol consumption on breast cancer: probabilistic bias analysis for adjustment of exposure misclassification bias and confounders
      Reza Pakzad, Saharnaz Nedjat, Hamid Salehiniya, Nasrin Mansournia, Mahyar Etminan, Maryam Nazemipour, Iraj Pakzad, Mohammad Ali Mansournia
      BMC Medical Research Methodology.2023;[Epub]     CrossRef
    • Food Intake and Colorectal Cancer
      Akshaya Kumar, Shanmugavel Chinnathambi, Magi Kumar, Ganesh N. Pandian
      Nutrition and Cancer.2023; 75(9): 1710.     CrossRef
    • Shared Lifestyle-Related Risk Factors of Cardiovascular Disease and Cancer: Evidence for Joint Prevention
      Farzad Masoudkabir, Noushin Mohammadifard, Arya Mani, Andrew Ignaszewski, Margot K. Davis, Golnaz Vaseghi, Marjan Mansourian, Christopher Franco, Carolyn Gotay, Nizal Sarrafzadegan, Francesco Giallauria
      The Scientific World Journal.2023; 2023: 1.     CrossRef
    • Alcohol and cancer: a denied association the statement of the Italian society on alcohol (Società Italiana di Alcologia—SIA)
      Gianni Testino, Emanuele Scafato, Valentino Patussi, Patrizia Balbinot, Andrea Ghiselli, Fabio Caputo
      Alcohol and Alcoholism.2023; 58(6): 683.     CrossRef
    • Diet-Wide Association, Genetic Susceptibility and Colorectal Cancer Risk: A Prospective Cohort Study
      Dongqing Jin, Ying Lu, Wei Wu, Fangyuan Jiang, Zihan Li, Liying Xu, Rongqi Zhang, Xue Li, Dong Chen
      Nutrients.2023; 15(22): 4801.     CrossRef
    • Male- and female-specific reproductive risk factors across the lifespan for dementia or cognitive decline: a systematic review and meta-analysis
      Shuang-Ling Han, De-Chun Liu, Chen-Chen Tan, Lan Tan, Wei Xu
      BMC Medicine.2023;[Epub]     CrossRef
    • Cancer risk based on alcohol consumption levels: a comprehensive systematic review and meta-analysis
      Seunghee Jun, Hyunjin Park, Ui-Jeong Kim, Eun Jeong Choi, Hye Ah Lee, Bomi Park, Soon Young Lee, Sun Ha Jee, Hyesook Park
      Epidemiology and Health.2023; 45: e2023092.     CrossRef
    • ‘Pretty in Pink’ and ‘Girl Power’: An analysis of the targeting and representation of women in alcohol brand marketing on Facebook and Instagram
      A.M. Atkinson, B.R. Meadows, C. Emslie, A. Lyons, H.R. Sumnall
      International Journal of Drug Policy.2022; 101: 103547.     CrossRef
    • Very-light alcohol consumption suppresses breast tumor progression in a mouse model
      Xiuxiu Wang, Min Jia, Yifei Mao, Zhenzhen Jia, Huilin Liu, Guiwen Yang, Shuo Wang, Baoguo Sun, Hongyan Zhang
      Food & Function.2022; 13(6): 3391.     CrossRef
    • Global, regional, and national cancer deaths and disability‐adjusted life‐years (DALYs) attributable to alcohol consumption in 204 countries and territories, 1990‐2019
      Saeid Safiri, Seyed Aria Nejadghaderi, Nahid Karamzad, Kristin Carson‐Chahhoud, Nicola Luigi Bragazzi, Mark J. M. Sullman, Amir Almasi‐Hashiani, Mohammad Ali Mansournia, Gary S. Collins, Jay S. Kaufman, Ali‐Asghar Kolahi
      Cancer.2022; 128(9): 1840.     CrossRef
    • Adherence to the Vegetable-Fruit-Soy Dietary Pattern, a Reference From Mediterranean Diet, Protects Against Postmenopausal Breast Cancer Among Chinese Women
      Shang Cao, Linchen Liu, Qianrang Zhu, Zheng Zhu, Jinyi Zhou, Pingmin Wei, Ming Wu
      Frontiers in Nutrition.2022;[Epub]     CrossRef
    • The effects of modest drinking on life expectancy and mortality risks: a population-based cohort study
      Yen-Tze Liu, June Han Lee, Min Kuang Tsai, James Cheng-Chung Wei, Chi-Pang Wen
      Scientific Reports.2022;[Epub]     CrossRef
    • Colon Cancer: From Epidemiology to Prevention
      Kyriaki Katsaounou, Elpiniki Nicolaou, Paris Vogazianos, Cameron Brown, Marios Stavrou, Savvas Teloni, Pantelis Hatzis, Agapios Agapiou, Elisavet Fragkou, Georgios Tsiaoussis, George Potamitis, Apostolos Zaravinos, Chrysafis Andreou, Athos Antoniades, Chr
      Metabolites.2022; 12(6): 499.     CrossRef
    • Associations Between Physical Activity and Alcohol Consumption in Rural Cancer Survivors
      Scherezade K. Mama, Natalia I. Heredia, Hannah Johnston, David E. Conroy
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Epidemiology beyond its limits
      Lauren E. McCullough, Maret L. Maliniak, Avnika B. Amin, Julia M. Baker, Davit Baliashvili, Julie Barberio, Chloe M. Barrera, Carolyn A. Brown, Lindsay J. Collin, Alexa A. Freedman, David C. Gibbs, Maryam B. Haddad, Eric W. Hall, Sarah Hamid, Kristin R. V
      Science Advances.2022;[Epub]     CrossRef
    • Review on recent development of quinoline for anticancer activities
      Mohan Ilakiyalakshmi, Ayyakannu Arumugam Napoleon
      Arabian Journal of Chemistry.2022; 15(11): 104168.     CrossRef
    • Relationship Between Physical Activity Levels and Thyroid Cancer Risk: A Prospective Cohort Study in Korea
      Anh Quynh Bui, Madhawa Gunathilake, Jeonghee Lee, Eun Kyung Lee, Jeongseon Kim
      Thyroid.2022; 32(11): 1402.     CrossRef
    • Frequent low dose alcohol intake increases gastric cancer risk: the Health Examinees-Gem (HEXA-G) study
      Hwi-Won Lee, Dan Huang, Woo-Kyoung Shin, Katherine de la Torre, Minkyo Song, Aesun Shin, Jong-Koo Lee, Daehee Kang
      Cancer Biology & Medicine.2022; 19(8): 1224.     CrossRef
    • Bewertung des Rotweinkonsums im Rahmen der mediterranen Ernährung – Eine systematische Literaturanalyse
      Benjamin Seethaler, Mirjam Fuchs, Julia Schumacher, Maryam Basrai, Marion Kiechle, Stephan C. Bischoff
      Aktuelle Ernährungsmedizin.2022; 47(05): 368.     CrossRef
    • What is behind the lifestyle risk factors for head and neck cancer?
      Anem Iftikhar, Mohammad Islam, Simon Shepherd, Sarah Jones, Ian Ellis
      Frontiers in Psychology.2022;[Epub]     CrossRef
    • Association of alcohol use with memory decline in middle-aged and older Chinese: a longitudinal cohort study
      Yu Meng Tian, Wei Sen Zhang, Chao Qiang Jiang, Feng Zhu, Ya Li Jin, Tong Zhu, Kar Keung Cheng, Lin Xu
      BMC Psychiatry.2022;[Epub]     CrossRef
    • Impact of Physical Activity on the Characteristics and Metabolic Consequences of Alcohol Consumption: A Cross-Sectional Population-Based Study
      Onni Niemelä, Aini Bloigu, Risto Bloigu, Anni S. Halkola, Markus Niemelä, Mauri Aalto, Tiina Laatikainen
      International Journal of Environmental Research and Public Health.2022; 19(22): 15048.     CrossRef
    • Current Developments in European Alcohol Policy: An Analysis of Possible Impacts on the German Wine Industry
      Frederik Nikolai Schulz, Barbara Richter, Jon H. Hanf
      Beverages.2022; 8(4): 75.     CrossRef
    • Polymorphisms in IL-17A Gene and Susceptibility of Colorectal Cancer in Bangladeshi Population: A Case-Control Analysis
      Md. Robiul Islam, Md. Abdul Aziz, Mohammad Shahriar, Mohammad Safiqul Islam
      Cancer Control.2022;[Epub]     CrossRef
    • Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population‐based cohort studies and two‐sample Mendelian randomization analyses
      Jue‐Sheng Ong, Eske M. Derks, Mikael Eriksson, Jiyuan An, Liang‐Dar Hwang, Douglas F. Easton, Paul P. Pharoah, Andrew Berchuck, Linda E. Kelemen, Keitaro Matsuo, Georgia Chenevix‐Trench, Per Hall, Stig E. Bojesen, Penelope M. Webb, Stuart MacGregor
      International Journal of Cancer.2021; 148(6): 1338.     CrossRef
    • Estimation of cancers caused by light to moderate alcohol consumption in the European Union
      Pol Rovira, Jürgen Rehm
      European Journal of Public Health.2021; 31(3): 591.     CrossRef
    • LncRNA PRNCR1 rs1456315 and CCAT2 rs6983267 Polymorphisms on 8q24 Associated with Lung Cancer
      Wei-Ling Yu, Jin-Jian Yao, Zong-Zhou Xie, Yan-Jing Huang, Sha Xiao
      International Journal of General Medicine.2021; Volume 14: 255.     CrossRef
    • Time trends of colorectal cancer incidence and associated lifestyle factors in South Korea
      Hayeong Khil, Sung Min Kim, SungEun Hong, Hyeon Min Gil, Eugene Cheon, Dong Hoon Lee, Young Ae Kim, NaNa Keum
      Scientific Reports.2021;[Epub]     CrossRef
    • Alcohol Consumption, HDL-Cholesterol and Incidence of Colon and Rectal Cancer: A Prospective Cohort Study Including 250,010 Participants
      Aage Tverdal, Gudrun Høiseth, Per Magnus, Øyvind Næss, Randi Selmer, Gun Peggy Knudsen, Jørg Mørland
      Alcohol and Alcoholism.2021; 56(6): 718.     CrossRef
    • Low-level alcohol consumption and cancer mortality
      Hyeonyoung Ko, Yoosoo Chang, Han-Na Kim, Jae-Heon Kang, Hocheol Shin, Eunju Sung, Seungho Ryu
      Scientific Reports.2021;[Epub]     CrossRef
    • Factors Associated with Women’s Unwillingness to Decrease Alcohol Intake to Decrease Breast Cancer Risk
      Jenna Matin, Rachel McFarland Lucia, Krustina Lal, Alyssa Columbus, Deborah Goodman, Kathryn Larsen, Argyrios Ziogas, Hannah Lui Park
      Journal of Primary Care & Community Health.2021;[Epub]     CrossRef
    • Past 6-Year Trends in Current Alcohol Use among Cyberbullied Adolescents
      George E. Higgins, Jason Nicholson, Catherine D. Marcum
      Substance Use & Misuse.2021; 56(6): 831.     CrossRef
    • Meme Kanserinden Korunmada ve Meme Kanseri Tedavisinde Akdeniz Diyetinin Etkisi
      Burcu DENİZ GÜNEŞ, Nilüfer ACAR TEK
      Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi.2021; 5(2): 442.     CrossRef
    • Global colorectal cancer burden in 2020 and projections to 2040
      Yue Xi, Pengfei Xu
      Translational Oncology.2021; 14(10): 101174.     CrossRef
    • Alcohol abstinence and mortality in a general population sample of adults in Germany: A cohort study
      Ulrich John, Hans-Juergen Rumpf, Monika Hanke, Christian Meyer, Charlotte Hanlon
      PLOS Medicine.2021; 18(11): e1003819.     CrossRef
    • Alcohol Use and Cancer in the European Union
      Jürgen Rehm, Kevin D. Shield
      European Addiction Research.2021; 27(1): 1.     CrossRef
    • Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes
      Firas Baidoun, Kholoud Elshiwy, Yasmine Elkeraie, Zahi Merjaneh, George Khoudari, Muhammad Talal Sarmini, Mohamed Gad, Muneer Al-Husseini, Anas Saad
      Current Drug Targets.2021; 22(9): 998.     CrossRef
    • Improving Knowledge that Alcohol Can Cause Cancer is Associated with Consumer Support for Alcohol Policies: Findings from a Real-World Alcohol Labelling Study
      Ashini Weerasinghe, Nour Schoueri-Mychasiw, Kate Vallance, Tim Stockwell, David Hammond, Jonathan McGavock, Thomas K. Greenfield, Catherine Paradis, Erin Hobin
      International Journal of Environmental Research and Public Health.2020; 17(2): 398.     CrossRef
    • Alcohol Consumption by Beverage Type and Risk of Breast Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies
      Qiuyu Sun, Weihong Xie, Yanli Wang, Feifei Chong, Mengmeng Song, Tiandong Li, Linping Xu, Chunhua Song
      Alcohol and Alcoholism.2020; 55(3): 246.     CrossRef
    • The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017
      Peng Ji, Yue Gong, Ming-Liang Jin, Xin Hu, Gen-Hong Di, Zhi-Ming Shao
      Frontiers in Oncology.2020;[Epub]     CrossRef
    • General and particular issues of etiopathogenesis of peptic ulcer and gastric cancer: current status of the problem
      A. M. Osadchuk, I. L. Davydkin, T. A. Gricenko, M. A. Osadchuk
      Terapevticheskii arkhiv.2020; 92(2): 97.     CrossRef
    • Risk Factors of Cardiovascular Disease according to Alcohol Behavioral Change after Cancer Diagnosis
      Eun Mi Bae, In Young Cho, Ji-Hye Jun, Kiheon Lee, Ju Young Kim, Woo Kyung Bae, Hyejin Lee, Jong Soo Han, Se Young Jung, Kee Hyuck Lee, Sarah Kim, Hye Yeon Koo, Sang Jin Cho, Houbuem Lee, Chuelmin Paek
      Korean Journal of Family Medicine.2020; 41(4): 222.     CrossRef
    • Joint effect of tobacco, alcohol, and oral HPV infection on head and neck cancer risk in the French West Indies
      Aviane Auguste, Jacqueline Deloumeaux, Clarisse Joachim, Stanie Gaete, Leah Michineau, Cécile Herrmann‐Storck, Suzy Duflo, Danièle Luce
      Cancer Medicine.2020; 9(18): 6854.     CrossRef
    • Impacts of Habitual Diets Intake on Gut Microbial Counts in Healthy Japanese Adults
      Takuya Sugimoto, Tatsuichiro Shima, Ryuta Amamoto, Chiaki Kaga, Yukiko Kado, Osamu Watanabe, Junko Shiinoki, Kaoru Iwazaki, Hiroko Shigemura, Hirokazu Tsuji, Satoshi Matsumoto
      Nutrients.2020; 12(8): 2414.     CrossRef
    • Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
      Sheela S. Reddy
      Current Hepatology Reports.2020; 19(4): 382.     CrossRef
    • Qualitative Study of Compliance with Nutritional Management in Colorectal Cancer Patient Undergoing Chemotherapy
      Heejung Park, Hyonson Kil, Wookyoun Cho
      Korean Journal of Community Nutrition.2020; 25(4): 303.     CrossRef
    • Heterogenous Effect of Risk Factors on Breast Cancer across the Breast Density Categories in a Korean Screening Population
      Boyoung Park, Se-Eun Lim, HyoJin Ahn, Junghyun Yoon, Yun Su Choi
      Cancers.2020; 12(6): 1391.     CrossRef
    • The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
      Jong Hwa Choi, Won Sohn, Yong Kyun Cho
      Clinical and Molecular Hepatology.2020; 26(4): 662.     CrossRef
    • Report on Recently (2017–20) Designed Quinoline‐Based Human Cancer Cell Growth Inhibitors
      Atukuri Dorababu
      ChemistrySelect.2020; 5(44): 13902.     CrossRef
    • Validating Breast Cancer Risk Prediction Models in the Korean Cancer Prevention Study-II Biobank
      Yon Ho Jee, Chi Gao, Jihye Kim, Seho Park, Sun Ha Jee, Peter Kraft
      Cancer Epidemiology, Biomarkers & Prevention.2020; 29(6): 1271.     CrossRef
    • Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship
      Giuseppe G. Caprio, Desiree Picascia, Marcello Dallio, Pietro P. Vitiello, Emilio F. Giunta, Vincenzo De Falco, Ludovico Abenavoli, Anna C. Procopio, Vincenzo Famiglietti, Erika Martinelli, Antonietta G. Gravina, Alessandro Federico, Fortunato Ciardiello,
      Reviews on Recent Clinical Trials.2020; 15(3): 164.     CrossRef
    • Laboratory test based assessment of WHO alcohol risk drinking levels
      Onni Niemelä, Ulla Nivukoski, Aini Bloigu, Risto Bloigu, Mauri Aalto, Tiina Laatikainen
      Scandinavian Journal of Clinical and Laboratory Investigation.2019; 79(1-2): 58.     CrossRef
    • Wein und Krebs – was zeigt die epidemiologie?
      N. Worm, Jean-Marie Aurand
      BIO Web of Conferences.2019; 12: 04002.     CrossRef
    • Association of Periodontitis with Oral Cancer: A Case-Control Study
      Y.J. Shin, H.W. Choung, J.H. Lee, I.C. Rhyu, H.D. Kim
      Journal of Dental Research.2019; 98(5): 526.     CrossRef
    • Does Alcohol Use Affect Cancer Risk?
      Jürgen Rehm, Isabelle Soerjomataram, Carina Ferreira-Borges, Kevin D. Shield
      Current Nutrition Reports.2019; 8(3): 222.     CrossRef
    • Dietary index scores and invasive breast cancer risk among women with a family history of breast cancer
      Joshua Petimar, Yong-Moon Mark Park, Stephanie A Smith-Warner, Teresa T Fung, Dale P Sandler
      The American Journal of Clinical Nutrition.2019; 109(5): 1393.     CrossRef
    • Impacts of unfavourable lifestyle factors on biomarkers of liver function, inflammation and lipid status
      Ulla Nivukoski, Markus Niemelä, Aini Bloigu, Risto Bloigu, Mauri Aalto, Tiina Laatikainen, Onni Niemelä, Pedro Tauler
      PLOS ONE.2019; 14(6): e0218463.     CrossRef
    • Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies
      Tung Hoang, Seung-Kwon Myung, Thu Thi Pham
      Cancer Research and Treatment.2019; 51(3): 1022.     CrossRef
    • Colorectal cancer epidemiology in Korea
      Aesun Shin, Doeun Jang, Sunho Choe, Young-Joo Won, Kyu-Won Jung, Ji Won Park, Seung-Yong Jeong
      Journal of the Korean Medical Association.2019; 62(8): 407.     CrossRef
    • Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
      NaNa Keum, Edward Giovannucci
      Nature Reviews Gastroenterology & Hepatology.2019; 16(12): 713.     CrossRef
    • Alcohol Exposure Impacts the Composition of HeLa-Derived Extracellular Vesicles
      Leandra B. Jones, Sanjay Kumar, Aliyah J. Curry, Jayde S. Price, Alexandre Krendelchtchikov, Brennetta J. Crenshaw, Courtnee’ R. Bell, Sparkle D. Williams, Tambre A. Tolliver, Sabita N. Saldanha, Brian Sims, Qiana L. Matthews
      Biomedicines.2019; 7(4): 78.     CrossRef
    • Joint tobacco smoking and alcohol intake exacerbates cancer risk in women– the Danish nurse cohort
      Jette Heberg, Mette Kildevæld Simonsen, Anne Kjaergaard Danielsen, Tobias Wirenfeldt Klausen, Vibeke Zoffmann, Thordis Thomsen
      European Journal of Oncology Nursing.2019; 43: 101675.     CrossRef
    • Wie hoch ist das Krebs-Risiko bei moderate Weinkonsum im Rahmen einer mediterranen Ernährung?
      N. Worma, P. Roca
      BIO Web of Conferences.2019; 15: 04003.     CrossRef
    • From scientific evidence to media and policy: Wine – part of a balanced diet or a health risk?
      U. Fradera, C. Stein-Hammer, P. Roca
      BIO Web of Conferences.2019; 15: 04004.     CrossRef
    • The individual and combined effects of alcohol consumption and cigarette smoking on site-specific cancer risk in a prospective cohort of 26,607 adults: results from Alberta’s Tomorrow Project
      Benjamin Viner, Amanda M. Barberio, Tiffany R. Haig, Christine M. Friedenreich, Darren R. Brenner
      Cancer Causes & Control.2019; 30(12): 1313.     CrossRef
    • STUDY OF KNOWN RISK FACTORS IN BREAST CANCER PATIENTS IN THE REGIONAL POPULATION
      Ashok Kumar, Abhilash Bipin Kumar Tirkey, Sumitoj Singh, Rajiv Devgan
      Journal of Evolution of Medical and Dental Sciences.2019; 8(18): 1446.     CrossRef
    • High-Risk Drinking in the Elderly
      Seung-Won Oh
      Korean Journal of Family Medicine.2018; 39(4): 209.     CrossRef
    • Epidemiology of Moderate Alcohol Consumption and Breast Cancer: Association or Causation?
      Samir Zakhari, Jan B. Hoek
      Cancers.2018; 10(10): 349.     CrossRef
    • Alcohol and Health
      Giovanni de Gaetano, Simona Costanzo
      Journal of the American College of Cardiology.2017; 70(8): 923.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Light Alcohol Drinking and Risk of Cancer: A Meta-Analysis of Cohort Studies
      Cancer Res Treat. 2018;50(2):474-487.   Published online May 22, 2017
      DOI: https://doi.org/10.4143/crt.2017.094
      Close
    • XML DownloadXML Download
    • 0
    • 1
    • 2
    Light Alcohol Drinking and Risk of Cancer: A Meta-Analysis of Cohort Studies
    Image Image Image
    Fig. 1. Flow diagram of identification of relevant studies.
    Fig. 2. Association between light alcohol drinking (≤ 1 drink/day) and the risk of female breast cancer in a random-effects meta-analysis. RR, relative risk; CI, confidence interval.
    Fig. 3. Association between light alcohol drinking (≤ 1 drink/day) and the risk of male colorectal cancer in a random-effects meta-analysis. RR, relative risk; CI, confidence interval.

    Fig. 1.

    Fig. 2.

    Fig. 3.

    Light Alcohol Drinking and Risk of Cancer: A Meta-Analysis of Cohort Studies
    Category Incidence
    		 Mortality
    No. of articles No. of studies No. of articles No. of studies
    Site of cancer
     Upper digestive tract
      Oral and pharynx 5 5 2 2
      Esophagus (SCC) 2 2 5 4
      Esophagus (ADC) and cardia 3 3 NA NA
      Head and neck 2 2 NA NA
     Gastrointestinal tract
      Stomach (non-cardia) 11 9 2 2
      Colorectum 16 16 6 5
      Colon 10 10 NA NA
      Rectum 9 9
     Hepatobiliary system
      Liver 2 2 2 2
      Pancreas 5 5 4 4
      Gallbladder NA NA 1 1
     Respiratory tract
      Lung 10 10 6 5
      Larynx 1 1 1 1
     Women's cancer
      Breast (female) 34 27 7 7
      Endometrium 9 9 NA NA
      Ovary 5 5 NA NA
      Cervix/Uterus 2 2 1 1
     Men's cancer
      Prostate 15 14 4 4
     Urological system
      Kidney 7 7 1 1
      Bladder 4 4 NA NA
     Others
      Thyroid 6 6 NA NA
      Hematologic malignancy 8 8 2 2
      Malignant melanoma 3 3 NA NA
    Country
     Asia
      China 3 2 NA NA
      Japan 5 4 2 2
      Korea 3 2 1 1
      Singapore 3 1 NA NA
      Honk Kong NA NA 1 1
     North America
      US 70 28 9 9
      Canada 4 2 1 1
     Europe
      UK 5 5 NA NA
      Sweden 6 3 NA NA
      Norway 1 1 NA NA
      Netherland 10 3 NA NA
      Lithuania 2 2 NA NA
      France 2 2 NA NA
      Finland 1 1 NA NA
      European countries 1 1 NA NA
      Denmark 5 3 NA NA
    Site of cancer Total No. of studies Population Very light drinking (≤ 0.5 drink/day)
    		 Light drinking (≤ 1 drink/day)
    		 Moderate drinking (1-2 drinks/day)
    No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%)
    Head and neck 2 Women/Men 1 1.11 (0.75-1.65) NA 2 1.00 (0.75-1.33) 0.0 2 1.18 (0.67-2.07) 63.8
    Oral and pharynx 5 Women/Men 0 NA NA 4 0.96 (0.84-1.11) 68.9 3 1.12 (1.01-1.24) 19.5
    Women 0 NA NA 3 0.95 (0.75-1.19) 77.6 3 1.18 (1.05-1.33) 0.0
    Men 0 NA NA 1 0.89 (0.79-1.00) NA 2 1.04 (0.93-1.17) 0.0
    Larynx 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
    Women 0 NA NA 1 1.13 (0.75-1.70) NA 1 1.74 (1.25-2.41) NA
    Men 0 NA NA 0 NA NA 0 NA NA
    Esophagus (SCC) 2 Women/Men 1 0.85 (0.42-1.73) NA 2 1.45 (0.90-2.33) 0.0 2 1.98 (1.25-3.14) 0.0
    Women 0 NA NA 0 NA NA 0 NA NA
    Men 0 NA NA 1 1.22 (0.62-2.44) NA 1 1.87 (0.99-3.53) NA
    Esophagus (ADC) and cardia 3 Women/Men 1 1.17 (0.69-1.98) NA 3 0.83 (0.52-1.33) 44.5 3 0.81 (0.56-1.17) 0.0
    Women 0 NA NA 0 NA NA 0 NA NA
    Men 0 NA NA 0 NA NA 0 NA NA
    Stomach, non-cardia 11 Women/Men 3 1.00 (0.78-1.30) 0.0 7 1.00 (0.95-1.07) 0.0 6 0.91 (0.78-1.06) 0.0
    Women 1 1.11 (0.71-1.73) NA 0 NA NA 0 NA NA
    Men 2 1.04 (0.66-1.64) 0.0 2 1.01 (0.92-1.11) 0.0 2 0.91 (0.68-1.20) 0.0
    Colorectum 16 Women/Men 6 1.10 (0.94-1.28) 39.7 14 1.04 (1.01-1.06) 0.0 10 1.10 (1.03-1.19) 41.0
    Women 2 0.92 (0.78-1.08) 0.0 7 1.02 (0.98-1.06) 0.0 5 1.04 (0.95-1.13) 4.4
    Men 3 1.31 (0.92-1.86) 47.3 6 1.06 (1.01-1.11) 0.0 6 1.19 (1.06-1.35) 10.6
    Colon 10 Women/Men 2 0.91 (0.55-1.49) 79.4 11 0.99 (0.93-1.05) 1.4 6 1.01 (0.88-1.15) 43.3
    Women 0 NA NA 5 1.12 (0.90-1.40) 60.4 5 1.03 (0.91-1.17) 28.4
    Men 1 1.42 (0.83-2.45) NA 5 1.02 (0.87-1.21) 0.0 5 1.08 (0.89-1.31) 0.0
    Rectum 9 Women/Men 2 1.47 (0.95-2.29) 0.0 10 1.04 (0.96-1.12) 0.5 7 1.03 (0.94-1.12) 0.0
    Women 0 NA NA 4 1.02 (0.93-1.11) 0.0 3 0.99 (0.90-1.09) 0.0
    Men 0 NA NA 3 1.07 (0.69-1.64) 0.0 2 1.35 (0.77-2.35) 0.0
    Liver 2 Women/Men 0 NA NA 2 0.95 (0.76-1.20) 0.0 2 1.26 (1.00-1.58) 0.0
    Women 0 NA NA 1 0.94 (0.72-1.21) NA 1 1.20 (0.93-1.55) NA
    Men 0 NA NA 0 NA NA 0 NA NA
    Pancreas 5 Women/Men 4 1.06 (0.87-1.30) 0.0 3 1.02 (0.83-1.26) 6.3 3 1.03 (0.86-1.23) 0.0
    Women 0 NA NA 0 NA NA 1 1.01 (0.53-1.91) NA
    Men 2 1.25 (0.90-1.74) 0.0 1 1.39 (0.75-2.56) NA 1 1.24 (0.66-2.32) NA
    Lung 10 Women/Men 3 0.89 (0.84-0.93) 6.9 10 0.91 (0.90-0.94) 0.0 8 0.98 (0.91-1.07) 50.0
    Women 2 0.82 (0.70-0.95) 12.9 4 0.90 (0.87-0.94) 0.0 4 1.05 (0.99-1.11) 0.0
    Men 1 0.86 (0.71-1.03) NA 3 0.91 (0.90-0.95) 0.0 4 0.98 (0.82-1.16) 52.1
    Breast (female) 34 Women 20 1.04 (1.01-1.07) 3.7 25 1.09 (1.06-1.12) 32.8 15 1.13 (1.11-1.15) 0.0
    Endometrium 9 Women 6 0.95 (0.80-1.12) 52.1 7 0.98 (0.93-1.03) 0.0 4 0.93 (0.84-1.04) 6.8
    Ovary 5 Women 2 1.00 (0.82-1.22) 0.0 5 1.02 (0.88-1.20) 52.4 4 1.20 (0.92-1.56) 66.6
    Cervix and uterus 2 Women NA NA NA 2 1.02 (0.88-1.19) 0.0 2 0.99 (0.83-1.17) 0.0
    Prostate 15 Men 3 1.16 (0.94-1.44) 0.0 13 1.04 (0.97-1.11) 50.0 3 1.04 (0.96-1.11) 0.0
    Kidney 7 Women/Men 2 0.73 (0.50-1.08) 0.0 7 0.90 (0.81-1.00) 0.0 3 0.93 (0.86-1.00) 0.0
    Women 1 0.75 (0.45-1.29) NA 2 0.79 (0.41-1.50) 66.9 1 0.93 (0.80-0.94) NA
    Men NA NA NA 3 0.90 (0.78-1.03) 0.0 1 0.94 (0.64-1.03) NA
    Bladder 4 Women/Men 2 1.22 (0.82-1.82) 27.5 5 1.09 (0.97-1.23) 0.0 4 1.06 (0.77-1.47) 64.2
    Women 0 NA NA 1 1.05 (0.92-1.21) NA 1 0.91 (0.77-1.07) NA
    Men 0 NA NA 1 1.31 (0.80-2.13) NA 0 NA NA
    Thyroid 6 Women/Men 1 1.01 (0.76-1.36) NA 6 0.89 (0.79-1.00) 0.0 3 0.68 (0.56-0.84) 0.0
    Women 0 NA NA 5 0.89 (0.78-1.01) 0.0 2 0.67 (0.53-0.85) 0.0
    Men 0 NA NA 1 0.62 (0.25-1.54) NA 1 0.69 (0.40-1.20) NA
    Hematologic malignancy 8 Women/Men 3 1.05 (0.87-1.26) 15.1 6 0.98 (0.91-1.05) 41.4 6 0.89 (0.81-0.99) 52.3
    Women 1 1.16 (0.88-1.54) NA 4 0.99 (0.93-1.06) 0.0 3 0.91 (0.81-1.02) 0.0
    Men 0 NA NA 2 0.98 (0.81-1.19) 54.2 2 0.90 (0.78-1.04) 0.0
    Malignant melanoma 3 Women/Men 0 NA NA 3 1.44 (1.18-1.76) 0.0 2 1.77 (1.35-2.33) 0.0
    Women 0 NA NA 2 1.32 (0.97-1.79) 0.0 1 1.70 (0.90-3.10) NA
    Men 0 NA NA 0 NA NA 1 0.90 (0.20-3.00) NA
    Site of cancer Total No. of studies Population Very light drinking (≤ 0.5 drink/day)
    		 Light drinking (≤ 1 drink/day)
    		 Moderate drinking (1-2 drinks/day)
    No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%)
    Oral and pharynx 2 Women/Men 0 NA NA 0 NA NA 0 NA NA
    Women 0 NA NA 0 NA NA 0 NA NA
    Men 0 NA NA 2 0.71 (0.24-2.16) 72.0 1 0.75 (0.27-2.06) NA
    Esophagus 4 Women/Men 0 NA NA 0 NA NA 0 NA NA
    Women 0 NA NA 0 NA NA 0 NA NA
    Men 0 NA NA 4 1.17 (0.98-1.39) 0.0 2 1.46 (0.93-2.16) 0.0
    Larynx 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
    Women 0 NA NA 0 NA NA 0 NA NA
    Men 0 NA NA 1 1.31 (0.60-2.85) NA 1 0.87 (0.32-2.35) NA
    Stomach 2 Women/Men 0 NA NA 3 0.81 (0.58-1.12) 49.5 2 1.11 (0.79-1.56) 43.6
    Women 0 NA NA 1 0.65 (0.44-0.98) NA 1 1.48 (0.85-2.57) NA
    Men 0 NA NA 2 0.95 (0.83-1.10) 0.0 1 1.00 (0.85-1.18) NA
    Colorectum 6 Women/Men 2 0.88 (0.70-1.12) 0.0 6 0.97 (0.83-1.14) 32.6 2 1.55 (0.67-3.58) 82.4
    Women 1 0.74 (0.53-1.03) NA 4 0.79 (0.58-1.06) 26.3 1 2.51 (1.31-4.82) NA
    Men 2 1.06 (0.72-1.55) 0.0 5 1.11 (0.95-1.28) 0.0 1 1.06 (0.80-1.40) NA
    Liver 2 Women/Men 0 NA NA 2 0.92 (0.81-1.04) 0.0 2 1.00 (0.88-1.14) 37.7
    Women 0 NA NA 2 0.78 (0.48-1.25) 0.0 1 1.80 (0.90-1.10) NA
    Men 0 NA NA 2 0.93 (0.81-1.06) 0.0 2 0.98 (0.91-1.07) 0.0
    Gallbladder 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
    Women 1 1.49 (0.59-3.74) NA 1 1.14 (0.28-4.70) NA 0 NA NA
    Men 0 NA NA 0 NA NA 0 NA NA
    Pancreas 4 Women/Men 0 NA NA 4 0.93 (0.78-1.11) 22.0 1 0.95 (0.72-1.27) 0.0
    Women 0 NA NA 1 0.66 (0.35-1.23) NA 1 0.50 (0.12-2.05) NA
    Men 1 0.52 (0.23-1.15) NA 3 1.01 (0.55-1.85) 55.8 1 0.98 (0.73-1.31) NA
    Lung 5 Women/Men 2 0.81 (0.69-0.94) 0.0 6 0.90 (0.79-1.04) 49.3 0 NA NA
    Women 1 0.70 (0.56-0.89) NA 3 1.03 (0.80-1.31) 43.1 1 0.94 (0.45-1.94) NA
    Men 2 0.84 (0.68-1.03) 0.0 5 0.79 (0.70-0.87) 0.0 1 0.78 (0.68-0.90) NA
    Breast 7 Women 2 0.79 (0.64-0.97) 0.0 6 1.06 (0.97-1.16) 31.5 2 1.04 (1.01-1.07) 0.0
    Cervix/Uterus 1 Women 0 NA NA 1 1.09 (0.50-2.35) NA 1 1.10 (0.25-4.79) NA
    Prostate 4 Men 2 0.92 (0.68-1.25) 0.0 1 1.14 (0.85-1.52) 0.0 1 1.75 (0.72-4.22) NA
    Kidney 1 Women/Men 0 NA NA 0 NA NA 0 NA NA
    Women 0 NA NA 0 NA NA 0 NA NA
    Men 0 NA NA 1 0.63 (0.35-1.12) NA 1 0.46 (0.23-0.93) NA
    Hematologic malignancy 2 Women/Men 0 NA NA 2 1.24 (0.40-3.86) 55.6 1 1.00 (0.63-1.60) NA
    Women 0 NA NA 1 3.26 (0.79-13.48) NA 0 NA NA
    Men 1 0.87 (0.49-1.53) NA 3 0.80 (0.54-1.18) 1.9 1 1.00 (0.63-1.60) NA
    Table 1. Number of articles and studies by organ site and country among 135 articles and 60 cohort studies

    SCC, squamous cell carcinoma; ADC, adenocarcinoma; NA, not available.

    Table 2. Association between very light, light, and moderate alcohol drinking and cancer incidence

    RR, relative risk; CI, confidence interval; NA, not applicable; SCC, squamous cell carcinoma; ADC, adenocarcinoma.

    Table 3. Association between very light, light, and moderate alcohol drinking and cancer mortality

    RR, relative risk; CI, confidence interval; NA, not applicable.

    Table 1.

    Table 2.

    Table 3.

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP